已收录 268922 条政策
 政策提纲
  • 暂无提纲
Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells
[摘要] BackgroundGlioma stem cells (GSCs) contribute to tumor recurrence and drug resistance. This study characterizes the tumorigenesis of CD133+ cells and their sensitivity to pharmacological inhibition.MethodsGSCs from human U87 and rat C6 glioblastoma cell lines were isolated via magnetic cell sorting using CD133 as a cancer stem cell marker. Cell proliferation was determined using the WST-1 assay. An intracranial mouse model and bioluminescence imaging were used to assess the effects of drugs on tumor growth in vivo.ResultsCD133+ cells expressed stem cell markers and exhibited self-renewal and enhanced tumor formation. Minocycline (Mino) was more effective in reducing the survival rate of CD133+ cells, whereas CD133− cells were more sensitive to inhibition by the signal transducer and activator of transcription 3 (STAT3) inhibitor. Inhibition of STAT3 decreased the expression of CD133+ stem cell markers. The combination of Mino and STAT3 inhibitor synergistically reduced the cell viability of glioma cells. Furthermore, this combination synergistically suppressed tumor growth in nude mice.ConclusionThe results suggest that concurrent targeting of different subpopulations of glioblastoma cells may be an effective therapeutic strategy for patients with malignant glioma.
[发布日期] 2017-12-29 [发布机构] 
[效力级别]  [学科分类] 
[关键词] Glioma;Cancer stem cells;Minocycline;STAT3;Combination therapy;Synergy [时效性] 
   浏览次数:7      统一登录查看全文      激活码登录查看全文